問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Cardiovascular Diseases

Division of General Internal Medicine

更新時間:2023-09-19

王怡智Wang, Yi-Chih
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 10 個月

篩選

List

41Cases

2025-11-14 - 2031-03-30

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
  • Condition/Disease

    Heart Failure With Preserved Ejection Fraction、 Heart Failure With Mildly Reduced Ejection Fraction Obesity

  • Test Drug

    subcutaneous injection

Participate Sites
6Sites

Not yet recruiting6Sites

2024-09-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

2018-03-20 - 2024-03-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting9Sites

2023-10-02 - 2030-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-07-01 - 2026-01-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-05-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-06-20 - 2026-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-06-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2012-12-01 - 2019-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2012-12-01 - 2014-06-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 2 3 4 5